Literature DB >> 20654583

On the retinal toxicity of intraocular glucocorticoids.

Alicia Torriglia1, Fatemeh Valamanesh, Francine Behar-Cohen.   

Abstract

Corticosteroids are hormones involved in many physiological responses such as stress, immune modulation, protein catabolism and water homeostasis. The subfamily of glucocorticoids is used systemically in the treatment of inflammatory diseases or allergic reactions. In the eye, glucocorticoides are used to treat macular edema, inflammation and neovascularization. The most commonly used glucocorticoid is triamcinolone acetonide (TA). The pharmaceutical formulation of TA is not adapted for intravitreal administration but has been selected by ophthalmologists because its very low intraocular solubility provides sustained effect. Visual benefits of intraocular TA do not clearly correlate with morpho-anatomical improvements, suggesting potential toxicity. We therefore studied, non-common, but deleterious effects of glucocorticoids on the retina. We found that the intravitreal administration of TA is beneficial in the treatment of neovascularization because it triggers cell death of endothelial cells of neovessels by a caspase-independent mechanism. However, this treatment is toxic for the retina because it induces a non-apoptotic, caspase-independent cell death related to paraptosis, mostly in the retinal pigmented epithelium cells and the Müller cells.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20654583     DOI: 10.1016/j.bcp.2010.07.012

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Sustained-release steroids for the treatment of diabetic macular edema.

Authors:  Alejandra Daruich; Alexandre Matet; Francine Behar-Cohen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

Review 2.  A Review of the Role of Intravitreal Corticosteroids as an Adjuvant to Antibiotics in Infectious Endophthalmitis.

Authors:  Dawn Ching Wen Ho; Aniruddha Agarwal; Cecilia S Lee; Jay Chhablani; Vishali Gupta; Manoj Khatri; Jayabalan Nirmal; Carlos Pavesio; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2016-11-16       Impact factor: 3.070

Review 3.  Glucocorticoid receptor signaling in the eye.

Authors:  Rania S Sulaiman; Mahita Kadmiel; John A Cidlowski
Journal:  Steroids       Date:  2017-11-10       Impact factor: 2.668

4.  Safety of intravitreal triamcinolone acetonide: an electrophysiologic and histopathological study in rabbits.

Authors:  Laila Hassan M El-Shazly; Amal Ahmad El-Gohary; Ghada Ghanem El-Hossary
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

Review 5.  Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine.

Authors:  Bernhard A Sabel; Jiaqi Wang; Lizbeth Cárdenas-Morales; Muneeb Faiq; Christine Heim
Journal:  EPMA J       Date:  2018-05-09       Impact factor: 6.543

Review 6.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

7.  Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.

Authors:  Hongkwan Cho; Siva P Kambhampati; Michael J Lai; Lingli Zhou; Grace Lee; Yangyiran Xie; Qiaoyan Hui; Rangaramanujam M Kannan; Elia J Duh
Journal:  Adv Ther (Weinh)       Date:  2020-11-09

8.  Temporal Association between Topical Ophthalmic Corticosteroid and the Risk of Central Serous Chorioretinopathy.

Authors:  Yuh-Shin Chang; Shih-Feng Weng; Jhi-Joung Wang; Ren-Long Jan
Journal:  Int J Environ Res Public Health       Date:  2020-12-17       Impact factor: 3.390

9.  Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model.

Authors:  Emilie Picard; Francine Behar-Cohen; Alejandra Daruich; Thara Jaworski; Hugues Henry; Marta Zola; Jenny Youale; Léa Parenti; Marie-Christine Naud; Kimberley Delaunay; Mathilde Bertrand; Marianne Berdugo; Laura Kowalczuk; Jeffrey Boatright
Journal:  Neurotherapeutics       Date:  2021-02-03       Impact factor: 7.620

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.